Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, 55455, USA.
Small Molecule Pharmaceutical Sciences, Genentech Inc., South San Francisco, California, 94080, USA.
AAPS J. 2022 Jul 25;24(5):87. doi: 10.1208/s12248-022-00721-1.
The purpose of this study was to develop and validate a simultaneous dissolution and absorption testing tool, the "artificial gut simulator" (AGS), for oral drug formulations. The AGS was constructed using hollow fibers and housed in a 3-mL UV spectrophotometric cuvette that provided a large surface area-to-volume ratio to simulate absorption at a physiological rate. A quasi-steady-state model describing absorption was developed and validated using a high aqueous solubility, BCS-I model compound, caffeine. This model was used to optimize the AGS operating parameters to simulate physiological gastric emptying and caffeine absorption, which was further input into a one-compartment pharmacokinetic (PK) model. The in vivo caffeine plasma concentration-time profiles matched those predicted by the PK model with in vitro input from the AGS. This work provides a framework for establishing an in vitro/in vivo correlation with high-permeability, BCS-II supersaturating drug formulations, which will be explored in the future studies.
本研究旨在开发和验证一种用于口服药物制剂的同时溶解和吸收测试工具,即“人工肠道模拟器”(AGS)。AGS 是使用中空纤维构建的,并安装在一个 3 毫升的紫外分光光度比色皿中,该比色皿提供了较大的表面积与体积比,以模拟生理速率下的吸收。使用高水溶性、BCS-I 模型化合物咖啡因开发并验证了描述吸收的准稳态模型。该模型用于优化 AGS 的操作参数,以模拟生理胃排空和咖啡因吸收,然后将其进一步输入到单室药代动力学(PK)模型中。体内咖啡因血浆浓度-时间曲线与 PK 模型预测的曲线相匹配,PK 模型的输入来自 AGS。这项工作为建立高渗透性、BCS-II 超饱和药物制剂的体外/体内相关性提供了一个框架,未来的研究将对此进行探索。